# Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC Genotype

> **NCT06247670** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **CAMP4 Therapeutics Corporation** · enrollment: 120 (estimated)

## Conditions studied

- Healthy Volunteers
- OTC Deficiency

## Interventions

- **DRUG:** CMP-CPS-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06247670
- **Lead sponsor:** CAMP4 Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06247670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06247670, "Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC Genotype". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06247670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*